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Abstract Natalizumab has been shown to be effective in
pivotal clinical trials in multiple sclerosis; however, the
patients in whom treatment is indicated in clinical practice
have a different clinical profile from those included in the
clinical trials. The aim of this study is therefore to collect
data on natalizumab use in everyday clinical practice in
Spain. The 86 participating centers throughout Spain sub-
mitted data on disease characteristics at baseline and after
treatment. Valid data were available for 1,364 patients
(69.3% women, 86.9% with relapsing–remitting disease).
Ninety-three percent had received prior therapy for multiple
sclerosis. For the 825 patients on treatment for at least a
year, the annualized relapse rate (ARR) decreased from
median 2.0 [mean 2.01, 95% confidence interval (CI)
1.92–2.11] in the year prior to natalizumab to 0.0 (mean
0.25, 95% CI 0.21–0.29) at 1 year (p \ 0.001). The
Expanded Disability Status Scale (EDSS) score decreased
from median 3.5 at baseline (mean 3.71, 95% CI 3.60–3.82)
to 3.0 (mean 3.37, 95% CI 3.25–3.49) (p \ 0.0001). The
discontinuation rate was 14%. One patient discontinued
natalizumab due to progressive multifocal leukoencepha-
lopathy (PML) and another due to probable PML (subse-
quently confirmed). Although our patients had more severe
disease than those in the pivotal study, a similar reduction in
ARR was observed. This finding is in line with previous
observational studies. The effect was independent of base-
line EDSS.
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Introduction
Natalizumab is a monoclonal antibody that interferes with
leukocyte trafficking into the central nervous system by
antagonizing the a4 subunit of integrin expressed on the
surface of activated T-cells [1, 2]. Such an action is thought
to reduce the inflammatory component of multiple sclerosis
(MS), particularly during the early relapsing–remitting
phases of the disease [3]. A number of randomized con-
trolled phase II and phase III studies have shown natal-
izumab to be effective at reducing the annualized relapse
rate (ARR) and also disease progression as measured using
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the Expanded Disability Status Scale (EDSS). In most
cases, a substantial reduction in disease activity according
to magnetic resonance imaging (MRI) measures has also
been documented [4–7]. Natalizumab has been on the
market in Spain since 2007, and as of July 2010, 1,865
patients had been treated.
Natalizumab was approved largely on the strength of the
pivotal AFFIRM study, which compared natalizumab
infusions with placebo infusions in patients who for the
most part had not received prior MS therapy [6]. However,
in view of the risk of progressive multifocal leukoen-
cephalopathy (PML)—developed by two patients in the
SENTINEL study [7], which compared natalizumab versus
the combination of natalizumab plus interferon b-1a IM—
the indication was limited to patients who have failed front-
line therapy or who have an aggressive form of the disease.
As a consequence, patients treated in clinical practice tend
to have more severe disease than those enrolled in the
AFFIRM study [8–12].
The aim of this multicenter, retrospective study is to
collect data on patients treated with natalizumab in Spain
in everyday clinical practice and to compare the patient and
disease characteristics both with those published in clinical
trials and with other observational studies.
Patients and methods
All Spanish centers that had treated at least one patient with
natalizumab before 31 May 2010 were invited to participate
in the study. To be included, patients had to be diagnosed
with MS and have received at least one dose of natalizumab
prior to this cut-off date. All patients gave written informed
consent for their data to be used in the study, which was
approved by the Ethics Committees of the participating
centers and notified to the Spanish Drug Agency. The
investigators retrospectively filled out electronic data-col-
lection forms (an Excel spreadsheet) for natalizumab-trea-
ted patients from their clinical records. Data were
transferred anonymously from the returned Excel forms to
the database to safeguard the privacy of the patients.
The data-collection forms included sections for demo-
graphic data (sex and date of birth), baseline disease data
[year of diagnosis of MS, prior treatments, clinical form of
MS prior to initiation of natalizumab treatment, EDSS
score prior to treatment with natalizumab, ARR prior to
treatment with natalizumab, and MRI data (presence of T1
Gd-enhancing lesions and T2-hyperintense lesions prior to
treatment)], details of natalizumab treatment (number of
natalizumab perfusions), and disease data after initiating
treatment (EDSS score at 6 and 12 months after starting
treatment, ARR after 12 months of treatment, and MRI
data after 12 months of treatment). In addition, safety data
were collected (adverse drug reactions, neutralizing anti-
bodies, hypersensitivity reactions, and reason for treatment
withdrawal when applicable). Data from the forms were
collected and analyzed by a contract research organization
(Phidea Marvin, Madrid, Spain).
Statistical analysis
Descriptive statistics were calculated for patient data
[mean, standard deviation (SD), minimum, median, maxi-
mum for continuous variables, and percentages for cate-
gorical variables]. Variables were compared using the
McNemar test or the Wilcoxon test as appropriate, and
statistical significance was set at p \ 0.05. Analysis was
performed with the SAS program.
Results
Data capture
Data were collected from 86 Spanish centers, correspond-
ing to an estimated 56% of all Spanish centers where na-
talizumab is prescribed and accounting for approximately
85% of natalizumab prescriptions in Spain.
Data were available for 1,415 patients. Fifty-one
patients were excluded from the subsequent analyses
because of inconsistency in the data (36 patients), first
administration of natalizumab before the patient’s 18th
birthday (14 patients), or missing number of infusions (one
patient). The final number of patients analyzed was there-
fore 1,364.
Patient characteristics
In the year prior to treatment the median ARR was 2.0
(range 1–14) (mean 2.01, 95% CI 1.94–2.08). The median
EDSS score at baseline was 3.5 (mean 3.77, 95% CI
3.68–3.86). Most patients had EDSS between 2 and 3 [478/
1,318 (36.3%)] and between 3.5 and 4.5 [349/1,318
(26.5%)]. Fifty-three patients (4.0%) had baseline EDSS
[6 points. The patients included predominantly had the
relapsing–remitting form (87%); the remainder had sec-
ondary progressive MS with relapses.
A large majority of patients had received prior MS
treatment [1,268/1,363 (93.0%)], and the median duration
of this prior treatment was 52 months (range 0–258
months). Subcutaneous (SC) interferon beta 1a was the
most common prior treatment, followed by interferon beta
1b SC (Table 1). In total, 603 patients (44.2%) had
received only one prior treatment while 665 (48.8%) had
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received two or more prior treatments (up to a maximum of
six). Overall, 113 (8.9%) had received prior immunosup-
pressive therapy (mainly mitoxantrone). The reasons for
switching to natalizumab were cited as lack of efficacy in
75.2%, poor tolerability in 18.5%, and patient decision in
6.2% (more than one reason possible). The median number
of natalizumab infusions received was 16.0 (range 1–50).
In total, 287 (21.0%) had received natalizumab for more
than 2 years. One patient, who had been enrolled in a
clinical trial with natalizumab, had received natalizumab
for more than 4 years (natalizumab has only been available
in Spain since 2007).
Safety data: discontinuation of treatment
Overall, 176/1,249 patients (14.1%) discontinued treat-
ment. Reasons for discontinuation were cited as lack of
efficacy [37/1,249 (3.0%)], tolerability [36/1,249 (2.9%)],
and patient decision [36/1,249 (2.9%)]. Other reasons for
discontinuation were pregnancy or desire to become
pregnant [15/1,249 (1.2%)], neutralizing antibodies [34/
1,082 (3.1%)], and hypersensitivity [46/1,284 (3.6%)]
(more than one reason possible).
Most discontinuations occurred in the first year [103/176
(58.5%), of which 55 (31.3%) occurred within 6 months of
starting natalizumab]. Discontinuations due to lack of
efficacy tended to occur between 6 and 12 months after
starting treatment [19/37 (51.4%)], whereas discontinua-
tions due to tolerability tended to occur in the first
6 months [20/36 (55.6%)].
Of note was one discontinuation due to PML after 13
infusions and another due to suspected PML (later con-
firmed) after 14 infusions. The patient with confirmed PML
had the secondary progressive form of the disease (EDSS
of 5.5 on starting treatment) and had undergone bone
marrow transplant prior to initiating treatment with natal-
izumab. The patient with suspected PML had the relaps-
ing–remitting form, but his EDSS score had increased from
4.5 in the year prior to treatment to 5.5 on initiating
treatment. She did not have a history of treatment with
immunosuppressants.
Limited data are available on patients after discontinu-
ation of natalizumab (n = 112). Of the 82 who were doc-
umented to have received treatment, 78 had details
available. The most common treatments after discontinua-
tion of natalizumab were glatiramer acetate [16/78 (20.5%)]
and mitoxantrone [13/78 (16.7)]. Reactivation of the dis-
ease was reported in 47 out of 136 patients with data
available (34.6%) during follow-up. Reactivation was in the
form of relapses in 93%, MRI lesions in 31%, and increased
EDSS in 50%, and almost half (47.6%) had more than one
form of disease reactivation. The median time to disease
reactivation was 3.5 months (range 1.0–24.0 months).
Safety data: hypersensitivity reactions, neutralizing
antibodies, and concomitant infections
Hypersensitivity reactions were reported in 46 patients
(3.6%), although as noted above, only ten of these patients
actually withdrew due to such reactions. Thirty-four
patients, that is, 2.5% of the entire population and 3.1% of
the 1,082 with information on neutralizing antibodies,
had positive status in an antibody test. We note, however,
that patients were only tested in the event of suspicion
of neutralizing antibodies and that this test had only
been performed in approximately 20% of these patients.
Table 1 Demographic and baseline disease characteristics




Mean ± SD age on diagnosis of MS, years 29.6 ± 8.50
Mean ± SD time since diagnosis of MS, years 9.62 ± 5.65
Mean ± SD age on starting natalizumab, years 39.2 ± 8.95
Clinical form of MS prior to starting natalizumab
Relapsing–remitting 1,173 (86.8%)




One prior treatment 603 (44.2%)
Two prior treatments 431 (31.6%)
[2 prior treatments 234 (17.1%)
Interferon beta 1a SC 655 (51.7%)
Interferon beta 1b SC 447 (35.3%)
Interferon beta 1a IM 364 (28.7%)






Other treatments 120 (9.5%)
EDSS score in year prior to treatment 3.0 (0.0–8.0)
Annualized relapse rate in year prior to starting
natalizumab
2.0 (1–14)
No. of T1 Gd-enhancing lesions prior to natalizumab
0 lesions 530 (47.7%)
1–5 lesions 467 (42.0%)
6–9 lesions 49 (4.4%)
[9 lesions 66 (5.9%)
EDSS Expanded Disability Status Scale, IM intramuscular, MS mul-
tiple sclerosis, SC subcutaneous
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Concomitant infections were reported by 144 patients out
of 1,283 with data available (11.2%) during natalizumab
treatment; none of these were considered severe.
Efficacy outcomes
For patients who completed at least 12 months of treat-
ment, the median ARR decreased from 2.0 (mean 2.01,
95% CI 1.92–2.11) in the year prior to treatment to 0.0
(mean 0.25, 95% CI 0.21–0.29) during the 12-month
treatment period [p \ 0.0001 (McNemar test)] (Table 2).
On stratification by baseline EDSS, similar decreases were
observed across the different initial disease severities
(Fig. 1). In addition, the percentage of patients with at least
one relapse decreased from 89% in the year prior to
treatment to 20% in the year after starting treatment.
The EDSS score also decreased [from median 3.5 at
baseline to 3.0 at 12 months (p \ 0.0001, Wilcoxon test),
mean from 3.71 (95% CI 3.60–3.82) at baseline to 3.37
(95% CI 3.25–3.49) at 12 months] (Table 2). Twenty-four
percent of the patients showed improvement in EDSS
(defined as a decrease of C1.0 point) and only 6% showed
worsening (defined as an increase of C1.0 point) between
baseline and 1 year after treatment [Table 3, p \ 0.0001
for the differences (McNemar test)], the rest (70%)
remaining stable.
Less than half the patients were free of Gd-enhancing
lesions in the year prior to starting natalizumab treatment
(Table 2), whereas in the year following start of treatment,
96.4% were free of such lesions [p \ 0.0001 (McNemar
test)]. Only 23/289 patients (8.0%) with baseline Gd-
enhancing lesions still had Gd-enhancing lesions after
1 year of treatment, whereas 10/274 patients (3.7%) with-
out baseline Gd-enhancing lesions developed such lesions
after 1 year of treatment. After 1 year of treatment, 84.5%
of patients were free of new T2-hyperintense lesions.
We defined a variable ‘‘disease free’’ as patients without
any of the following: worsening EDSS (C1 point increase),
presence of relapses, and presence of Gd-enhancing and
Table 2 Efficacy outcomes for patients on treatment for at least 12 months
Outcome measure Baseline At 12 months/during 12-month treatment period
n Value n Value
Annualized relapse ratea 826 Median 2.0 (0–14) 825 Median 0.0 (0–4)b
Mean 2.01 (1.92–2.11) Mean 0.25 (0.21–0.29)
Percentage of patients with at least one relapsea 826 733 (88.7%) 825 168 (20.4%)
Basal EDSS score 839 Median 3.50 (0–8.5) 839 3.00 (0–7.5)c
Mean 3.71 (3.60–3.82) Mean 3.37 (3.25–3.49)
Patients with Gd-enhancing lesions at baseline 563 289 (51.3%) 563 33 (5.9%)
Results presented as median (range), mean (95% confidence interval), or absolute number (%)
EDSS Expanded Disability Status Scale
a In the year prior to baseline
b p \ 0.001 versus baseline (Wilcoxon test)
c p \ 0.001 versus baseline (McNemar test)
Fig. 1 Change in annualized relapse rate (year prior to and year after
starting natalizumab treatment for all patients in treatment for at least
12 months) by baseline Expanded Disability Status Scale score.
Percentages indicate relative reductions in the ARR between the year
before treatment and the year on treatment
Table 3 Summary of change in disease status according to Expanded
Disability Status Scale score
Change in disease
status
Time period relative to baseline
-12–0 months 0–6 months 6–12 months
Improvement 3.55 17.52 23.77
Stability 68.14 78.68 69.98
Worsening 28.31 3.8 6.25
Improvement defined as decrease C1 point on Expanded Disability
Status Scale, stability as\1 point change, and worsening as increase
C1 point over time. Only patients in treatment for 12 months inclu-
ded. The differences were statistically significant [p \ 0.0001
(McNemar test)]
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new T2-hyperintense lesions on MRI. According to this
definition, 63% were free of disease during the year of
treatment with natalizumab.
Of the 178 patients (13%) who had a secondary pro-
gressive (SP) form of the disease, 102 received treatment
with natalizumab for at least 12 months. For these patients,
the median ARR of 1.0 (mean 1.27, 95% CI 1.07–1.48) the
year prior to the treatment decreased to 0 (mean 0.13, 95%
CI 0.05–0.21) after 1 year of treatment. The median EDSS
score at baseline for these patients was 6.0 (mean 5.54,
95% CI 5.33–5.74), and at 12 months showed little varia-
tion (median 6, mean 5.32, 95% CI 5.06–5.58).
Thirty-three percent of the SP patients showed an
improvement in EDSS and only 15% showed worsening
between baseline and 1 year after treatment; the rest (53%)
remained stable. In total, 73% of the SP patients were free
of disease (according to the above definition) during the
year of treatment with natalizumab.
Discussion
Although randomized clinical trials provide the highest
level of evidence for the efficacy of a given drug, their
restrictive inclusion criteria and necessarily rigid protocols
may compromise their relevance for clinical practice.
Moreover, certain safety signals may only become apparent
when the drug has been administered to large numbers of
patients and so may not be detected in clinical trials during
drug development. It is therefore important to conduct
observational studies with a view to providing data from
real clinical practice. In the case of natalizumab, the need
for ‘‘real-life’’ data is particularly pertinent given that the
final approved indications limit use of the drug to patients
who have failed front-line therapies and those with highly
active disease. In the present study, we retrospectively
collected data from a large sample of natalizumab-treated
patients, accounting for approximately 85% of patients
treated with this drug in Spain.
As expected, ARRs in the year prior to treatment and
baseline EDSS were higher in our study than those reported
in the pivotal AFFIRM trial [6]. Nevertheless, despite a
higher pretreatment ARR, the ARR in our study in the year
after treatment was similar to that seen in the AFFIRM
trial. Of note is that the decrease in the number of relapses
is observed regardless of baseline EDSS, even in patients
with baseline EDSS [6.0 (the AFFIRM trial did not
include any patients with baseline EDSS [6.0). Also of
note was a significant decrease in EDSS for patients who
completed 12 months of treatment (from median EDSS 3.5
to 3.0 and from mean EDSS 3.77 to 3.38).
A number of points need to be addressed when inter-
preting the results of an observational study; for example,
patients who are included may be those who the treating
physicians consider will do well on treatment. In addition,
patients who do not complete 12 months of treatment with
natalizumab may be more likely to have poor outcomes if
they stay on therapy, and these patients are often not
considered in the final efficacy analysis of observational
studies. In our study, 37 patients withdrew due to lack of
efficacy (among other possible reasons). Even if all patients
who discontinued treatment (14% of total sample analyzed)
were considered as efficacy failures, rough calculations
based on a sample that either completed 12 months of
treatment or discontinued treatment suggest that the treat-
ment effect would still be considerable (approximately
70% free of relapses, which is closer to the 77% observed
in the active treatment arm of the AFFIRM trial).
Another possible confounder in the interpretation of
observational studies with no control arm is that the
treatment effect may be partly explained by regression to
the mean. Thus, patients are likely to start natalizumab
treatment during moments of high disease activity and this
activity would subside to a certain extent anyway,
regardless of treatment. In addition, we should also bear in
mind the tendency for fewer exacerbations as MS pro-
gresses, although the period of observation here was
probably too short to have a major impact on the results. In
our study, the decrease in ARR observed was 87.6% when
calculated relative to the previous year for all patients and
75.6% when calculated for patients on treatment for 1 year.
These values are very similar to the relative decrease in
ARR at 1 year observed between the active treatment and
placebo arm of the AFFIRM trial (68%), so that the effect
of regression to the mean was probably small in our study.
Particularly interesting are the results obtained in patients
already in the SP phase of the disease.
The retrospective nature of data collection may also
introduce a bias into the study results. Given these caveats
in the interpretation of observational studies, it is reassur-
ing that other observational studies performed in similar
patient populations in Germany, Switzerland, Denmark,
Italy, France, Sweden, and Spain show similar results [8–
17]. Table 4 summarizes the baseline characteristics of the
principal European observational studies. As in our study,
patients appear to have more severe disease than those
patients enrolled in the AFFIRM trial, reflecting the
approved indications for natalizumab. Patients in the
Danish study by Oturai et al. [9], however, appeared to
have a higher ARR in the year prior to treatment and a
higher baseline EDSS than the rest. This perhaps suggests
that, in Danish clinical practice, natalizumab is reserved for
patients with more active or severe disease. It is encour-
aging to see that, despite different methodologies and
presumably some variation in clinical practice and treat-
ment protocols in the different countries, good efficacy is
1818 J Neurol (2012) 259:1814–1823
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observed in terms of reducing ARR and EDSS (Table 5).
In all cases, the ARR is reduced to 0.2–0.3. An important
outcome measure of treatment is whether patients are dis-
ease free. Definitions vary, but in our study, we considered
patients who had stable EDSS (increase\1.0), no relapses,
and no Gd-enhancing or new T2-hyperintense lesions on
MRI at 1 year. According to our definition, 63% of the
patients were disease free at 1 year. This is similar to the
68% reported in the study by Prosperini et al. [11] using a
similar definition.
Our data are also in agreement with the findings to date
of the Tysabri Observational Program (TOP), which has
enrolled more than 3,000 patients treated with natalizumab
in a clinical practice setting [18]. As of June 2010, 2,150
patients had been enrolled (58% with EDSS C3.5 com-
pared with 46% in our study). The mean ARR before
starting natalizumab was 1.98. After natalizumab treat-
ment, the ARR had decreased to 0.26. A similar picture
also emerges from the STRATA study, which enrolled
patients who had participated in clinical trials for a further
48 weeks of treatment [19]. Thus the ARR remained low
(0.18), even after median total number of natalizumab
infusions of 37.
The discontinuation rate in our study was 14%, which is
slightly higher than most of the other observational studies
(Table 6). This might be partly explained by the longer
duration of follow-up than in most other studies. There was
one discontinuation due to PML and one due to probable
PML. Given that the case of suspected PML was later
confirmed, the incidence of PML in our study was 0.15%.
This is somewhat higher than in an Italian observational
study of the safety data which reported a rate of 0.03% [13]
but lower than the 0.27% reported by a surveillance study
in Sweden [15].
In a review of data from clinical trials, Yousry et al. [20]
concluded that the risk of PML was approximately 0.1%.
This figure, however, included two cases from the SEN-
TINEL clinical trial in which natalizumab was given in
combination with interferon beta 1a, and the approved label
forbids concomitant treatment with other disease-modifying
Table 4 Comparison of patients enrolled in observational studies and the AFFIRM trial






Putzki et al. [8] Germany and
Switzerland/5
97 (six previously untreated) C12 months 2.3 3.4
Oturia et al. [9] Denmark/2 234 (175 after switching from






Sangalli et al. [10] Italy/3 285 (233 after switching
treatment, 52 treatment
naı¨ve)
Up to 2 years 2.13 Not reported
Outteryck et al.
[12]
France/not statedb 384 (5.6% treatment naı¨ve;
efficacy data for 127)
C12 months 2.19 3.53
Prosperini et al.
[11]
Italy/1 190 (efficacy data for 169) Median 15 (range
1–29 months)
2.0 3.4a
Mancardi et al. [15] Italy/164 2,971 – – –
Putzki et al. [16] Switzerland/3 85 (after failure of DMT) Median 17.2 (range
12–31.4 months)
2.0 3.1
Piehl et al. [17] Sweden/36 1,115 Mean 22 months – 3.86c
Ferna´ndez et al.
[18]
Spain/1 77 Mean 14.7 months 0.96 3.18
Horga et al. [19] Spain 112 Mean 15.8 months 2.25 4.0
Ferna´ndez et al.d Spain/86 1,415 Median 16 (range 1–50) 2.23 3.23
AFFIRM/Polman
et al. [4]
Multinational/99 627 (natalizumab) 2 years 1.53 (natalizumab) 2.53
315 (placebo) 1.50 (placebo)
ARR annualized relapse rate, DMT disease-modifying therapy, EDSS Expanded Disability Status Scale
a Median
b Data reported for two regions
c For the 363 patients who completed 24 months of treatment
d This study
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therapies. As of March 2011, 102 cases of PML had been
confirmed, in more than 78,800 patients exposed, corre-
sponding to incidence of approximately 0.1% [21].
According to several studies [22, 23], the risk of PML
increases with prior immunosuppressant exposure and
treatment duration.
Both cases of PML reported in our study occurred after
approximately 1 year of treatment, and both patients had
high EDSS scores. One patient had undergone hemato-
poietic stem cell transplantation. Given its high toxicity,
such an intervention has only been considered in patients
with refractory disease [24]. Although PML has occa-
sionally been reported as a complication of hematopoietic
stem cell transplantation, it is generally considered rare in
this type of intervention [25]. Therefore, it is possible that
prior hematopoietic stem cell transplantation increases the
risk of PML of natalizumab treatment. In the case of the
second patient, no risk factors of note were identified and
the patient had not received immunosuppressants. An
algorithm for risk stratification has recently been proposed,
Table 5 Comparison of efficacy in observational studies and the AFFIRM trial
Reference ARR at 1 year Decrease in ARR
at 1 year with respect










at 1 year (%)
Putzki et al. [8] 0.2 91 80.4 0.4 10
Oturia et al. [9] 0.68 73 63 – 9
Sangalli et al. [10] 0.26 88 84 (78% at 2 years) – –
Outteryck et al. [12] 0.59 73 60 0.5 –
Prosperini et al. [11] 0.22 90a 85a 0.2c –
Putzki et al. [16] 0.27 87 78b 0.2 7
Piehl et al. [17] – – – 0.48d –
Ferna´ndez et al. [18] 0.13 86 – 0.05 –
Horga et al. [19] 0.24 89 80.3 0.2 9.2
Ferna´ndez et al.f 0.25 88 80 0.5e 6
AFFIRM/Polman et al. [4] 0.26 (natalizumab) 83 77 (natalizumab) – 13 (natalizumab)
0.81 (placebo) 54 56 (placebo) 21 (placebo)
ARR annualized relapse rate, EDSS Expanded Disability Status Scale
a Calculated for entire follow-up period (up to 29 months)
b Calculated for entire follow-up period (median 17.2 months)
c At 15 months follow-up
d For the 363 patients who completed 24 months of treatment
e Change in median
f This study
Table 6 Comparison of safety
outcomes and the AFFIRM trial
a Only reported if leading to
discontinuation
b Persistent and leading to
discontinuation
c Only patients with suspected
antibodies were tested for
neutralizing antibodies.
Nevertheless the percentage is
calculated with respect to the
total population on the
assumption that antibodies were







Putzki et al. [8] 8 (8.2%) 2 (2.1%)a 4 (4.1%)b
Oturia et al. [9] 27 (12%) 9 (3.8%) 7 (2.9%)
Sangalli et al. [10] 34 (12%) 18 (6.3%) 19 (6.6%)
Outteryck et al. [12] 35 (9.1%) 15 (3.9%) 5 (1.3%)b
Prosperini et al. [11] 31 (16.3%) 4 (2.1%)a 19 (10%)c
Putzki et al. [16] 10 (12%) 2 (2.4%)a 6 (7.1%)b
Piehl et al. [17] 116 (10.4%) – 39 (3.9%)
Ferna´ndez et al. [18] 13 (16.8%) 1 (1.3%) 9 (11.7%)
Horga et al. [19] 16 (14.4%) 5 (4.5%) –
Ferna´ndez et al.d 176 (14%) 46 (3.6%) 34 (3.1%)c
AFFIRM/Polman et al. [4] 3.8% (natalizumab) 9% (natalizumab) 57 (9%)
4.8% (placebo) 4% (placebo) –
1820 J Neurol (2012) 259:1814–1823
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based on prior immunosuppressant therapy, anti-John
Cunningham (JC) virus antibody status, and treatment
duration [2 years [21]. The antibody status in these
patients was unknown. Almost 10% of our patients had
received prior immunosuppressive therapy and 21% had
received more than 2 years of treatment and none of these
had developed PML at the time of data collection, apart
from the above-mentioned cases.
In conclusion, the present observational study in a large
population provides further support for the efficacy of na-
talizumab in a clinical practice setting. The sharp decrease in
relapse rate in the year following initiation of natalizumab
treatment in patients with more severe disease than those
included in the pivotal trial was in line with other observa-
tional studies performed in different countries, with different
methodologies and with different treatment protocols.
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GEXNE Group: authors (hospital) (number of patients
included in the study)
Montalba´n Gairı´n, X., Tintore´, M. (H. Universitario Vall
d0Hebron - CEM-Cat, Barcelona) (110); Ferna´ndez, O´.,
Guerrero M., Leo´n A, Alonso A., Ferna´ndez V., Leyva L.
(H. Regional Universitario Carlos Haya, Ma´laga) (96);
A´lvarez Lafuente, R., Arroyo Gonza´lez, R., (H. Clı´nico
San Carlos, Madrid) (90); Gamero, M.A., Garcı´a Moreno,
J.M., Izquierdo Ayuso, G., Navarro Mascarell, G., Pa´ramo
Camino, M.D., Ruiz-Pen˜a, J.L. (H. Universitario Virgen
Macarena, Sevilla) (88); Pe´rez Lo´pez, J.L. (H. Sierrallana,
Torrelavega) (68); Arbizu Urdiaı´n, T. (H. de Bellvitge,
Barcelona) (55); Ma´laga, I., Oliva Nacarino, P., Tun˜o´n
A´lvarez, A. (H. General de Asturias, Oviedo) (41); Ayuso
Blanco, T., Bujanda Alegrı´a, M., Lacruz Bescos, F., Sori-
ano Herna´ndez, G. (Complejo Hospitalario de Navarra, H.
A, Pamplona) (38); Herna´ndez Clares, R., Meca Lallana,
J.E. (H. Virgen de La Arrixaca, Murcia) (35); Herna´ndez,
M.A. (H. Universitario Ntra. Sra. de la Candelaria, Tene-
rife) (32); Aguilar-Amat, M.J., Ferna´ndez Pe´rez, M., Oreja-
Guevara, C. (H. Universitario La Paz, Madrid) (31); Ramio´
i Torrenta, L. (H. Universitario Dr. Josep Trueta, Girona)
(28); Agu¨era Morales, E., Sa´nchez Lo´pez, F. (H. Univer-
sitario Reina Sofı´a, Co´rdoba) (25); A´lvarez-Cermen˜o, J.C.,
Costa-Frossard, L. (H. Ramo´n y Cajal, Madrid) (24); Mu-
n˜oz Garcı´a, M. (H. Xeral-Cı´es, Vigo) (23); Coret Ferrer, F.,
Navarre´-Gimeno A. (H. Clı´nico Universitario Valencia,
Valencia) (22); Asensio Huerga, A.B., Olascoaga, J. (H.
Donostia, San Sebastia´n) (22); de Andre´s Frutos, C.,
Martı´nez Gine´s, M.L. (H. General Universitario Gregorio
Maran˜o´n, Madrid) (22); Arnal Garcı´a, C. (H. Virgen de las
Nieves, Granada) (22); Milla´n-Pascual, J., Turpı´n Fenoll,
L. (Complejo Hospitalario La Mancha - Centro, Alcazar de
San Juan) (20); Alarcia, R., Ara, J.R., Sa´nchez-Carteyron,
A. (H. Universitario Miguel Servet, Zaragoza) (20);
Blanco, Y. Saiz, A. (H. Clinic. IDIBAPS, Barcelona) (19);
Pe´rez Sempere, A. (H. General Alicante, Alicante) (18);
Padilla Parrado, F. (H. Clı´nico Universitario Virgen de La
Victoria, Ma´laga) (17); Argente, J. H. Universitario Puerta
Del Mar, Ca´diz) (16); Arias, M., Dapena, M.D. (H. Clı´nico
Universitario Santiago de Compostela, Santiago de Com-
postela) (15); Pe´rez Ruiz, D. (H. Comarcal El Bierzo,
Leo´n) (15); Ferias, I., Gracia Gil, J., Rallo Gutie´rrez, B. (H.
General de Albacete, Albacete) (15); Carrera, D., Ramos,
C. (H. Germans Trias i Pujol, Badalona) (15); Barrero, F.J.,
Ferna´ndez-Ortega, J.D. (H. San Cecilio, Granada) (15);
Yusta Izquierdo, A. (H. Universitario de Guadalajara,
Guadalajara) (15); Oterino Dura´n, A. (H. Universitario
Marque´s de Valdecilla, Santander) (15); Sua´rez Moro, R.
(H. Valle del Nalo´n, Langreo) (14); Ferna´ndez-Bolan˜os
Porras, R. (H. Universitario de Valme, Sevilla) (13); Otano,
M. (Complejo Hospitalario de Navarra, H. B, Pamplona)
(13); Cervello´, A., Parra Martı´nez, J. (Consorcio H. Gen-
eral Universitario Valencia, Valencia) (12); Fraile, A.,
Te´llez, N. (H. Clı´nico Universitario de Valladolid, Valla-
dolid) (12); Bonaventura, I. (H. Mutua de Terrassa, Ter-
rassa) (12); Bowakim Dib, W., Tola-Arribas, M.A. (H.
Universitario Rı´o Hortega, Valladolid) (12); Munteis, E.
(H. del Mar, Barcelona) (11); I´n˜iguez, C. (H. Clı´nico
Universitario Lozano Blesa, Zaragoza) (10); Are´s-Luque,
A., Villafani-Echazu´, J. (H. de Leo´n, Leo´n) (10); Iglesias,
F. (H. General Yagu¨e, Burgos) (10); Marzo, M.E. (H. San
Pedro, Logron˜o) (9); Escartin, A., Lo´pez Gonza´lez, M. (H.
Santa Creu i Sant Pau, Barcelona) (9); Marco Igual, M. (H.
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de Sabadell, Sabadell) (8); Batlle i Nadal, J. (H. Santa
Tecla, Tarragona) (8); Calles, C., Nun˜ez V. (H. Son Dureta,
Palma de Mallorca) (8); Mallada Frechı´n, J. (H. Virgen de
la Salud de Elda, Elda) (8); Eguia, P. (H. Doctor Jose´
Molina Orosa, Lanzarote) (7); Meca-Lallana, V. (H. Uni-
versitario de La Princesa, Madrid) (7); Reyes Ya´nez, M.P.
(H. Universitario Insular de Gran Canarias, Las Palmas de
Gran Canaria) (7); Ayuso Peralta, L., Rubio Pe´rez, L. (H.
Universitario Prı´ncipe de Asturias, Alcala´ de Henares) (7);
Casado, J.L., Gonza´lez Oria, C., Ucle´s Sa´nchez, A. (H.
Universitario Virgen del Rocı´o, Sevilla) (7); Caminero, A.
(Complejo Hospitalario Ntra. Sra. de Sonsoles, A´vila) (6);
Cano, A. (H. de Mataro´, Mataro´) (6); Berenguer, L., Pe´rez
Carmona, N. (H. Marina Baixa, Villajoyosa) (6); Pato Pato,
A. (H. POVISA, Vigo) (6); Guijarro-Castro, C. (H. Uni-
versitario 12 De Octubre, Madrid) (6); Miralles Martı´nez,
A. (H. Universitario Infanta Sofı´a, San Sebastia´n de los
Reyes) (6); Rodrı´guez Garcı´a, E. (H. Universitario Severo
Ochoa, Legane´s) (6); Losada Lo´pez, M. (Fundacio´n
Jime´nez Dı´az, Madrid) (5); Aguirre Sa´nchez, J.J. (H.
Infanta Cristina, Badajoz) (5); Sua´rez Ferna´ndez, G. (H.
Ntra. Sra. del Prado, Talavera de la Reina) (5); Carod-
Artal, F.J., Lo´pez Martı´nez, A. (H. Virgen de La Luz,
Cuenca) (5); Garcı´a Montero, M.R. (H. Virgen de La Sa-
lud, Toledo) (5); A´lvarez de Arcaya, A. (H. de Txagorritxu,
Vitoria) (4); Go´mez Gutie´rrez, M. (H. San Pedro de Al-
ca´ntara, Ca´ceres) (4); Domı´nguez-Mora´n, J.A., Peiro´
Vilaplana, C. (H. Universitario De La Ribera, Alzira) (4);
Garcı´a-Monco´, C., Mediavillam J., Sa´nchez Menoyo, J.L.
(H. de Galdakao-Usansolo, Galdakao) (3); Landete Pasc-
ual, L. (H. Dr. Peset, Valencia) (3); Lacruz Ballester, L. (H.
Francesc de Borja, Gandı´a) (3); Ballabriga Planas, J. (H.
Son Lla´tzer, Palma de Mallorca) (3); Aladro, Y. (H. Uni-
versitario de Getafe, Getafe) (3); Castillo, L., Borrega, L.
(H. Universitario Fundacio´n Alcorco´n, Alcorco´n) (3); Perla
Muedra, C., Valero Merino, C. (H. Arnau de Villanova,
Valencia) (2); Quı´lez Martı´nez, A. (H. Arnau de Villanova,
Lleida) (2); Sistiaga, C. (H. Bidasoa y Policlı´nica Gip-
uzkoa, Hondarribia) (2); Mun˜oz Ma´laga, A. (H. de Jerez,
Jerez de la Frontera) (2); Navarre´-Gimeno, A. (H. de
Sagunto, Valencia) (2); Gonza´lez Platas, M. (H. Univer-
sitario Canarias, Santa Cruz de Tenerife) (2); Carmona, O.
(Fundacio´ Salut Emporda´, Figueras) (1); Mendoza Rodrı´-
guez, A. (H. General de Segovia, Segovia) (1); Taleti, E. L.
(H. General Mateu Orfila, Mao´) (1); Romero Lo´pez, J. (H.
Meixoeiro, Vigo) (1); Jarauta Salvador, F. (H. Reina Sofı´a,
Tudela) (1).
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